查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924632

血庫市場按產品類型、最終用戶、採集方法、應用和技術分類－2026-2032年全球預測

Blood Bank Market by Product Type, End User, Collection Method, Application, Technology - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血液銀行市場價值將達到 107.9 億美元，到 2026 年將成長到 116.3 億美元，到 2032 年將達到 204.1 億美元，年複合成長率為 9.52%。

關鍵市場統計數據
基準年 2025 107.9億美元
預計年份：2026年 116.3億美元
預測年份 2032 204.1億美元
複合年成長率 (%) 9.52%

一個將整個醫療系統的經營團隊重點與臨床需求、營運韌性和技術進步連結起來的血庫生態系統策略框架

血庫產業正處於策略轉折點，臨床需求、技術創新和日益嚴格的監管壓力正在重新定義血液製品的採集、加工和分發方式。本文闡述了領導者需要了解的關鍵營運、科學和商業動態，以應對短期衝擊和實現長期轉型。文章重點分析了供應鏈韌性、產品差異化以及醫院系統、診斷中心和研究機構等各相關人員期望之間的相互作用，從而為相關問題提供了背景。

對於醫療保健領域的領導者而言，技術、臨床和監管力量的融合正在重塑血庫的營運、供應策略和品管重點。

血液庫環境正經歷變革性的轉變，這主要受技術成熟、臨床實踐發展和監管力度加大的推動。自動化處理平台和就地檢驗的日益普及，已開始重塑檢查室工作流程，從而加快結果報告速度並提高標準化程度。同時，捐血篩檢和病原體減少技術的進步，提高了安全裕度，迫使檢查室和供應商重新評估資金配置和供應商夥伴關係。

了解不斷變化的關稅政策如何影響整個血庫供應鏈的籌資策略、來源多元化和協作緊急時應對計畫。

美國近期關稅調整對血庫產業的供應鏈、籌資策略和跨境夥伴關係產生了連鎖反應。部分試劑、醫療拋棄式產品和低溫運輸設備的關稅上調，導致許多營運投入品的到岸成本增加，迫使採購團隊重新評估籌資策略，並探索替代供應商和近岸外包方案。因此，各機構不得不權衡成本壓力與產品安全和臨床供應不間斷這一不可妥協的需求。

透過細分市場分析，將血液服務生態系統中產品、最終用戶、採集方法、應用和技術方面的差異映射到客製化的營運和商業策略。

透過精準的市場區隔觀點，我們可以發現每種產品類型、最終用戶、採集方法、應用領域和技術都檢驗不同的營運和商業影響。例如，冷沉澱、新鮮冷凍血漿和冷凍血漿、單採或混合血小板、去白血球或洗滌紅血球以及全血等產品類型，在加工需求、儲存限制和臨床應用模式方面存在顯著差異，從而導致各自獨特的供應鏈和品管需求。

從區域觀點，將美洲、歐洲、中東和非洲以及亞太地區的營運重點與基礎設施、法規和臨床需求連結起來。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的營運模式、監管方式和夥伴關係機會的形成至關重要。在美洲，一體化的醫院系統和大規模區域血液網路推動了集中籌資策略和健全的物流體系。同時，法規環境強調嚴格的品管和可追溯性，影響各機構如何建構其庫存和捐血計畫。區域內的跨境合作也為特殊成分的緊急時應對計畫提供了支持。

競爭定位、技術合作和服務差異化如何影響血液銀行價值鏈中供應商的策略和採購偏好？

血庫生態系統內的競爭格局揭示出，專業供應商、平台提供者和臨床服務機構正競相投資產品差異化、服務商品搭售和技術整合。領先的儀器製造商和試劑供應商正在拓展產品組合，納入整合自動化解決方案、軟體支援的庫存管理和數據分析服務，以幫助檢查室減少人工操作並提高合規性。同時，臨床服務供應商透過保證服務品質、快速反應能力和區域配送網路來確保關鍵組件的及時供應，從而實現差異化競爭。

為領導者提供切實可行的、優先排序的行動指南，以增強韌性、協調臨床和籌資策略，並加速血庫採用以價值主導的技術。

產業領導者應制定一系列切實可行的優先事項，以平衡即時營運穩定與中期策略轉型。首先，選擇性地投資於自動化和數位化可追溯性項目，以直接降低人為錯誤率並提高庫存可見性，並分階段實施，以避免對核心臨床服務造成干擾。其次，透過供應商多元化、靈活的合約談判（考慮關稅波動）以及盡可能評估近岸製造方案，增強採購韌性。

本研究採用混合方法，結合專家的直接訪談和系統性的第二手資料分析，以確保對血庫運作和策略有嚴謹、實用的見解。

本分析的調查方法結合了針對性的初步研究和嚴謹的二次分析，以確保其可靠性和相關性。初步數據包括對臨床負責人、輸血醫學專業人員、血站管理人員和採購負責人的結構化訪談，旨在了解當地的營運挑戰、技術應用障礙和策略重點。這些訪談旨在檢驗假設、探索新的應用案例，並揭示不同地區工作流程和供應動態的差異。

一份簡潔而全面的分析報告，強調了在血液服務領域實現彈性運作、技術賦能的工作流程以及夥伴關係主導的改進的戰略必要性。

總之，血庫產業目前正經歷一場意義深遠的變革時期，臨床發展、技術進步和供應鏈動態的交匯融合，既帶來了挑戰，也帶來了機會。採取策略性策略，優先推動目標自動化、強化採購和加強臨床協作的機構，將更有利於確保醫療服務的連續性，並提高營運效率。同樣重要的是，需要建立健全的資料管治、加強人才培養，並具備在地化適應能力，以維持高品質的服務交付。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的血庫市場

  • 冷沉澱物
  • 電漿
    • 新鮮冷凍血漿
    • 冷凍血漿
  • 血小板
    • 血小板分離術
    • 混合血小板
  • 紅血球
    • 白血球耗竭的紅血球
    • 洗滌過的紅血球
  • 全血

第9章 依最終用戶分類的血庫市場

  • 血庫
  • 診所
  • 診斷中心
  • 醫院
  • 研究所

第10章：以採集方式分類的血庫市場

  • 血液分離術
  • 全血

第11章 依應用分類的血庫市場

  • 診斷
  • 研究
  • 輸血

第12章 科技驅動的血庫市場

  • 自動化
  • 手動的
  • 照護端

第13章 各地區的血庫市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血庫市場（以血庫集團分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國血庫市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血庫市場

第17章：中國血庫市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Blood Bank Computer Systems
  • Cordlife Group Limited
  • Cryo-Cell International, Inc.
  • Danaher Corporation
  • FamiCord Group
  • Fresenius SE & Co. KGaA
  • GE Healthcare
  • Grifols, SA
  • Haemonetics Corporation
  • Hoffmann-La Roche AG
  • J Mitra & Company Pvt. Ltd.
  • Johnson & Johnson
  • Macopharma SAS
  • MAK-SYSTEM
  • MedTech Solutions
  • Medtronic plc
  • Nipro Corporation
  • Oracle Corporation
  • Terumo Corporation
  • WellSky Corporation
Product Code: MRR-7A380DA7C3E7

The Blood Bank Market was valued at USD 10.79 billion in 2025 and is projected to grow to USD 11.63 billion in 2026, with a CAGR of 9.52%, reaching USD 20.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.79 billion
Estimated Year [2026] USD 11.63 billion
Forecast Year [2032] USD 20.41 billion
CAGR (%) 9.52%

A strategic framing of the blood bank ecosystem that ties clinical demand, operational resilience, and technological progress to executive priorities across healthcare systems

The blood bank environment is at a strategic inflection point where clinical demand, technological innovation, and regulatory rigor converge to redefine how blood products are collected, processed, and distributed. This introduction frames the critical operational, scientific, and commercial dynamics that leaders must understand to navigate short-term disruptions and long-term transformation. It sets the stage by highlighting the interplay between supply chain resilience, product differentiation, and stakeholder expectations across hospital systems, diagnostic centers, and research institutions.

Over recent years, advances in automation, donor screening technology, and inventory management have reduced variability while increasing throughput, yet persistent challenges remain in donor recruitment, cold chain integrity, and equitable access to specialized components such as platelets and cryoprecipitate. Consequently, executives are being asked to reconcile clinical imperatives with cost containment, regulatory compliance, and evolving reimbursement models. This broader context underscores why operational excellence and strategic foresight are essential for maintaining continuity of care.

Drawing on a synthesis of technical developments and operational lessons, this introduction prepares readers to examine subsequent sections that explore structural shifts, policy impacts, segmentation-driven opportunities, and regional dynamics. By grounding the discussion in pragmatic realities rather than speculative projections, the text equips decision-makers with a clear lens for prioritizing investments, partnerships, and process improvements across the blood bank ecosystem.

How converging technological, clinical, and regulatory forces are reshaping blood bank operations, supply strategies, and quality management priorities for healthcare leaders

The landscape of blood banking is undergoing transformative shifts driven by technological maturation, evolving clinical practices, and heightened regulatory scrutiny. Increasing adoption of automated processing platforms and point of care testing has begun to reshape laboratory workflows, enabling faster turnaround times and improved standardization. At the same time, advancements in donor screening and pathogen-reduction technologies are enhancing safety margins, prompting laboratories and suppliers to reassess capital allocation and vendor partnerships.

Simultaneously, clinical practice trends are altering demand profiles for specific blood components. Precision transfusion strategies and tighter transfusion thresholds have elevated the importance of component optimization, while growth in complex surgeries and aging populations sustains demand for specialized products such as leukoreduced and washed red blood cells. These clinical drivers intersect with logistics innovations, including just-in-time inventory models and digital cold-chain monitoring, which together improve availability while reducing wastage.

Regulatory pressures and quality frameworks are also reshaping operational priorities. Laboratories and collection centers are investing in robust traceability systems and data governance to meet inspection readiness and to facilitate rapid product recalls when necessary. As a result, organizations that proactively integrate technological capabilities with process redesign and workforce upskilling will be best positioned to capitalize on these transformative shifts and to deliver resilient, high-quality blood services across care settings.

Understanding how evolving tariff policies are driving procurement strategies, supplier diversification, and collaborative contingency planning across the blood bank supply chain

Recent tariff changes in the United States have created a ripple effect across supply chains, procurement strategies, and cross-border partnerships in the blood bank sector. Increased duties on certain reagents, medical disposables, and cold-chain equipment have amplified landed costs for many operational inputs, prompting procurement teams to reassess sourcing strategies and to explore alternative suppliers or nearshoring options. Consequently, organizations are balancing cost pressures against the non-negotiable needs of product safety and uninterrupted clinical supply.

These trade adjustments have also heightened the importance of transparent supplier agreements and long-term contracting to stabilize input costs. Procurement functions are working more closely with clinical leadership to prioritize critical items and to adjust inventory policies where clinically acceptable. In parallel, vendors are responding by diversifying manufacturing footprints and offering bundled services that can mitigate tariff exposure, such as localized assembly or service contracts that reduce the need for cross-border goods movement.

Importantly, the cumulative effects of tariffs have encouraged collaborative responses among healthcare providers, regional blood networks, and manufacturers to develop contingency plans that preserve patient care continuity. Strategic initiatives now emphasize supply chain visibility, scenario planning, and contractual flexibility so that clinical operations remain insulated from sudden policy or cost fluctuations while still maintaining compliance and product integrity.

A segmented analysis that maps product, end-user, collection, application, and technology distinctions to tailored operational and commercial strategies across the blood services ecosystem

Disaggregating the market through a precise segmentation lens reveals differentiated operational and commercial implications across product types, end users, collection methods, applications, and technologies. When examining product types such as cryoprecipitate, plasma in its fresh frozen and frozen variants, platelets available as apheresis or pooled units, red blood cells offered as leukoreduced or washed products, and whole blood, it becomes clear that processing requirements, storage constraints, and clinical utilization patterns vary considerably, driving distinct supply chain and quality management needs.

End users including blood banks, clinics, diagnostic centers, hospitals, and research institutes each bring unique demand signals and service level expectations. Blood banks orchestrate collection and distribution while hospitals and clinics focus on point-of-care readiness. Diagnostic centers and research institutes prioritize sample integrity and traceability for testing and experimental applications. Collection methods, whether apheresis or whole blood, further shape operational workflows, donor recruitment strategies, and equipment investments, as apheresis enables targeted component collection while whole blood collection supports broader inventory flexibility.

Application categories such as diagnostic use, research purposes, and transfusion therapy determine handling protocols and regulatory oversight. Meanwhile, technology choices-automated platforms, manual processes, and point of care solutions-influence throughput, error rates, and capital expenditure profiles. Taken together, these segmentation dimensions provide a framework for tailoring clinical protocols, infrastructure investments, and commercial engagement strategies in ways that align with operational priorities and patient-centered outcomes.

A regionally informed perspective that connects infrastructure, regulation, and clinical demand across Americas, Europe Middle East & Africa, and Asia-Pacific to operational priorities

Regional dynamics are pivotal in shaping operational models, regulatory approaches, and partnership opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated hospital systems and large regional blood networks drive centralized procurement strategies and robust logistics frameworks, while the regulatory environment emphasizes stringent quality control and traceability, influencing how organizations structure inventory and donor programs. Cross-border collaboration within the region also supports contingency planning for specialized components.

Europe, Middle East & Africa presents a mosaic of regulatory regimes and infrastructure maturity, where national policies and regional harmonization efforts influence donor engagement models and distribution networks. Investment priorities often include upgrading cold-chain capabilities and standardizing testing protocols to mitigate variability and to support equitable access across urban and rural areas. In the Asia-Pacific region, rapid modernization of healthcare infrastructure, a growing base of tertiary care facilities, and expanding research activity are increasing demand for advanced component processing and automation, even as supply challenges and donor mobilization remain focal concerns.

Together, these regional characteristics underscore the importance of geographically informed strategies that balance centralized capabilities with localized execution. By aligning technology adoption, workforce development, and partnership frameworks to regional strengths and constraints, organizations can enhance resilience, improve patient outcomes, and capture strategic advantages in their respective markets.

How competitive positioning, technology partnerships, and service differentiation are shaping supplier strategies and procurement preferences across the blood bank value chain

Competitive dynamics within the blood bank ecosystem reveal a mix of specialized suppliers, platform providers, and clinical service organizations that are investing in product differentiation, service bundling, and technological integration. Leading device manufacturers and reagent suppliers are expanding their portfolios to include integrated automation solutions, software-enabled inventory management, and data analytics services that help laboratories reduce manual steps and improve compliance. At the same time, clinical service providers are differentiating through quality-of-service commitments, rapid response capabilities, and regional distribution networks that support timely access to critical components.

Partnerships between technology vendors, blood centers, and healthcare systems are becoming more strategic, focusing on interoperability, digital traceability, and workflow optimization. Companies that can demonstrate validated clinical benefits, lower total cost of ownership, and scalable implementation pathways tend to be favored in procurement evaluations. Moreover, smaller niche providers continue to innovate in specialized segments such as pathogen reduction, advanced donor screening assays, and component-specific storage solutions, creating avenues for collaboration and acquisition by larger firms seeking to broaden their clinical utility.

Overall, competitive positioning in this landscape hinges on the ability to couple robust product performance with strong service models, regulatory support, and data-driven outcomes. Vendors and service organizations that prioritize customer-centric implementation, long-term training, and outcomes measurement will be better positioned to secure sustained engagement from hospitals, blood networks, and research institutions.

Practical and prioritized actions for leaders to strengthen resilience, align clinical and procurement strategies, and accelerate value-driven technology adoption in blood banking

Industry leaders should pursue a set of actionable priorities that balance immediate operational stabilization with medium-term strategic transformation. First, invest selectively in automation and digital traceability initiatives that directly reduce manual error rates and enhance inventory visibility, while sequencing implementation to avoid disruption to core clinical services. Next, strengthen procurement resilience by diversifying suppliers, negotiating flexible contracts that account for tariff volatility, and evaluating nearshore manufacturing options where feasible.

In addition, adopt a clinical alignment approach that integrates transfusion stewardship with product lifecycle management, ensuring that clinical teams are engaged in demand forecasting, component utilization reviews, and supply optimization. Workforce development is equally critical: implement targeted training programs to upskill lab personnel on new platforms and quality systems, and create cross-functional teams to manage change. Strategic partnerships with technology vendors should emphasize interoperability, outcome validation, and shared implementation risk to accelerate adoption while preserving clinical assurance.

Finally, prioritize data governance and analytics capabilities that enable proactive quality oversight, traceability, and performance measurement. By linking operational metrics with clinical outcomes, organizations can make evidence-based investment decisions, reduce wastage, and demonstrate value to payers and institutional stakeholders. Taken together, these actions will help organizations maintain continuity of care while advancing toward more efficient, technology-enabled models of blood services provision.

A mixed-methods approach blending primary expert interviews and systematic secondary synthesis to ensure rigorous, actionable insights into blood bank operations and strategy

The research methodology underpinning this analysis combined targeted primary inquiry with rigorous secondary synthesis to ensure robustness and relevance. Primary inputs included structured interviews with clinical leaders, transfusion medicine specialists, blood center executives, and procurement professionals to capture frontline operational challenges, technology adoption barriers, and strategic priorities. These interviews were designed to validate hypotheses, explore emerging use cases, and surface region-specific nuances in workflows and supply dynamics.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance, technical white papers, and vendor documentation to map technological capabilities, quality frameworks, and process standards. The analysis employed data triangulation to reconcile differing perspectives and to identify consistent patterns across sources. Where possible, case examples and implementation anecdotes were used to illustrate practical lessons and to highlight scalable best practices.

Quality assurance steps included expert review cycles, methodologic transparency, and iterative refinement of findings in response to stakeholder feedback. This mixed-methods approach provided a balanced view of operational realities and strategic opportunities, enabling conclusions and recommendations that are grounded in both empirical observation and technical plausibility.

A concise synthesis that reinforces the strategic imperatives for resilient operations, technology-enabled workflows, and partnership-driven improvements across blood services

In conclusion, the blood bank sector is navigating a period of meaningful change in which clinical evolution, technological progress, and supply chain dynamics converge to create both challenges and opportunities. Organizations that adopt a strategic posture-prioritizing targeted automation, procurement resilience, and clinical alignment-will be better able to ensure continuity of care and to realize efficiency gains. Equally important is the need for robust data governance, workforce development, and regional adaptability to sustain high-quality service delivery.

As stakeholders respond to tariff pressures, regulatory expectations, and shifting demand profiles for specific components, collaborative models and technology-enabled workflows will become increasingly central to operational success. By focusing on validated outcomes, interoperable solutions, and scalable implementation strategies, leaders can navigate near-term disruptions while building durable capabilities that support patient-centered transfusion care. The path forward demands disciplined investment, pragmatic partnerships, and continuous performance measurement to translate innovation into measurable clinical and operational value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Bank Market, by Product Type

  • 8.1. Cryoprecipitate
  • 8.2. Plasma
    • 8.2.1. Fresh Frozen Plasma
    • 8.2.2. Frozen Plasma
  • 8.3. Platelets
    • 8.3.1. Apheresis Platelets
    • 8.3.2. Pooled Platelets
  • 8.4. Red Blood Cells
    • 8.4.1. Leukoreduced Red Blood Cells
    • 8.4.2. Washed Red Blood Cells
  • 8.5. Whole Blood

9. Blood Bank Market, by End User

  • 9.1. Blood Banks
  • 9.2. Clinics
  • 9.3. Diagnostic Centers
  • 9.4. Hospitals
  • 9.5. Research Institutes

10. Blood Bank Market, by Collection Method

  • 10.1. Apheresis
  • 10.2. Whole Blood

11. Blood Bank Market, by Application

  • 11.1. Diagnostic
  • 11.2. Research
  • 11.3. Transfusion

12. Blood Bank Market, by Technology

  • 12.1. Automated
  • 12.2. Manual
  • 12.3. Point Of Care

13. Blood Bank Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Bank Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Bank Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Blood Bank Market

17. China Blood Bank Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Asahi Kasei Corporation
  • 18.7. B. Braun Melsungen AG
  • 18.8. Becton, Dickinson and Company
  • 18.9. Bio-Rad Laboratories, Inc.
  • 18.10. Blood Bank Computer Systems
  • 18.11. Cordlife Group Limited
  • 18.12. Cryo-Cell International, Inc.
  • 18.13. Danaher Corporation
  • 18.14. FamiCord Group
  • 18.15. Fresenius SE & Co. KGaA
  • 18.16. GE Healthcare
  • 18.17. Grifols, S.A.
  • 18.18. Haemonetics Corporation
  • 18.19. Hoffmann-La Roche AG
  • 18.20. J Mitra & Company Pvt. Ltd.
  • 18.21. Johnson & Johnson
  • 18.22. Macopharma SAS
  • 18.23. MAK-SYSTEM
  • 18.24. MedTech Solutions
  • 18.25. Medtronic plc
  • 18.26. Nipro Corporation
  • 18.27. Oracle Corporation
  • 18.28. Terumo Corporation
  • 18.29. WellSky Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD BANK MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD BANK MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD BANK MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD BANK MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD BANK MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD BANK MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD BANK MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD BANK MARKET SIZE, BY CRYOPRECIPITATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD BANK MARKET SIZE, BY CRYOPRECIPITATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD BANK MARKET SIZE, BY CRYOPRECIPITATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD BANK MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD BANK MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD BANK MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD BANK MARKET SIZE, BY FRESH FROZEN PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD BANK MARKET SIZE, BY FRESH FROZEN PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD BANK MARKET SIZE, BY FRESH FROZEN PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD BANK MARKET SIZE, BY FROZEN PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD BANK MARKET SIZE, BY FROZEN PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD BANK MARKET SIZE, BY FROZEN PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD BANK MARKET SIZE, BY PLATELETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD BANK MARKET SIZE, BY PLATELETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD BANK MARKET SIZE, BY PLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS PLATELETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS PLATELETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS PLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD BANK MARKET SIZE, BY POOLED PLATELETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD BANK MARKET SIZE, BY POOLED PLATELETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD BANK MARKET SIZE, BY POOLED PLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD BANK MARKET SIZE, BY LEUKOREDUCED RED BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD BANK MARKET SIZE, BY LEUKOREDUCED RED BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD BANK MARKET SIZE, BY LEUKOREDUCED RED BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD BANK MARKET SIZE, BY WASHED RED BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD BANK MARKET SIZE, BY WASHED RED BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD BANK MARKET SIZE, BY WASHED RED BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD BANK MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD BANK MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD BANK MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD BANK MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD BANK MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD BANK MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD BANK MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD BANK MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD BANK MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD BANK MARKET SIZE, BY APHERESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD BANK MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD BANK MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD BANK MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD BANK MARKET SIZE, BY TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD BANK MARKET SIZE, BY TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD BANK MARKET SIZE, BY TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD BANK MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD BANK MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD BANK MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD BANK MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD BANK MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD BANK MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD BANK MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD BANK MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD BANK MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD BANK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BLOOD BANK MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD BANK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. GCC BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 168. GCC BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 195. G7 BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. G7 BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 204. NATO BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 208. NATO BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD BANK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA BLOOD BANK MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA BLOOD BANK MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA BLOOD BANK MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA BLOOD BANK MARKET SIZE, BY PLATELETS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA BLOOD BANK MARKET SIZE, BY RED BLOOD CELLS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA BLOOD BANK MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA BLOOD BANK MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA BLOOD BANK MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BLOOD BANK MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)